CTL019: Phase II data

Data from 23 evaluable patients with relapsed or refractory CLL in a Phase II trial showed that CTL019

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE